The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Illumina is a diagnostics & research business based in the US. Illumina shares (ILMN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $100.80 – an increase of 6.34% over the previous week. Illumina employs 8,970 staff and has a trailing 12-month revenue of around $4.3 billion.
| Latest market close | $100.80 |
|---|---|
| 52-week range | $68.70 - $156.66 |
| 50-day moving average | $82.20 |
| 200-day moving average | $112.42 |
| Wall St. target price | $108.88 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.08 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $100.34 from 2025-07-02
| 1 week (2025-06-27) | 5.86% |
|---|---|
| 1 month (2025-06-04) | 20.66% |
| 3 months (2025-04-04) | 35.30% |
| 6 months (2025-01-03) | -26.23% |
| 1 year (2024-07-03) | -4.69% |
|---|---|
| 2 years (2023-07-03) | -45.17% |
| 3 years (2022-07-01) | 185.8366 |
| 5 years (2020-07-02) | 362.9377 |
Valuing Illumina stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Illumina's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Illumina's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.622. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Illumina's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Illumina's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $958 million.
The EBITDA is a measure of a Illumina's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.3 billion |
|---|---|
| Operating margin TTM | 17.67% |
| Gross profit TTM | $3 billion |
| Return on assets TTM | 4.96% |
| Return on equity TTM | -23.85% |
| Profit margin | -22.27% |
| Book value | $14.89 |
| Market Capitalization | $15 billion |
TTM: trailing 12 months
We're not expecting Illumina to pay a dividend over the next 12 months.
Illumina's shares were split on a 1028:1000 basis on 24 June 2024 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1028 shares. This wouldn't directly have changed the overall worth of your Illumina shares – just the quantity. However, indirectly, the new 2.7% lower share price could have impacted the market appetite for Illumina shares which in turn could have impacted Illumina's share price.
Over the last 12 months, Illumina's shares have ranged in value from as little as $68.7 up to $156.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Illumina's is 1.326. This would suggest that Illumina's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc.
0DTE options offer fast profits, but come with steep risks, rapid decay and zero recovery time.
Investing is more accessible than you may think. Here are five ways to start investing when you have little money to invest.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
We review the Kalshi trading platform and explain how investors can use it as a hedge for their investments.
Market capitalization can help investors determine a company’s market value to predict growth, but there are some considerations to keep in mind.
A firm’s book value and market value can help you measure a stock’s true worth. Learn more.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
A deep dive into the highlights and limitations of Robinhood.